Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition Roche reported a 9% increase in third-quarter sales, driven by strong ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

Roche stock gained on the news. Please watch the video at Investors.com - How Novo Nordisk, Wegovy And Ozempic Are Changing The Weight-Loss Game For Patients And Investors The deal will give Swiss ...

Short interest in Roche Holding AG (OTC:RHHBY) decreased during the last reporting period, falling from 3.57M to 2.59M. This put -% of the company's publicly available shares short. Short interest ...

Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella. Catalent stock faces uncertainty as several pharma companies voice ...

stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro. The company entered into an agreement with Roche Holdings AG (OTC:RHHBY ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Roche (OTCQX:RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of a certain type of breast cancer with a PIK3CA mutation. The agency ...

Roche's stock demonstrated resilience on the Swiss Stock Exchange SIX, fluctuating between 268.70 CHF and 272.20 CHF with a trading volume exceeding 247,000 shares. Despite a slight dip of 0.61% ...

View Roche Holding AG (RHHBF) current and estimated P/E ratio data provided by Seeking Alpha.